Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism.

Authors

Maysa Abu-Khalaf
Chun Wang
Zhenchao Zhang
Rui Luo
Weelic Chong
Daniel P Silver
Frederick Fellin
Rebecca Jaslow
AnaMaria Lopez
Terrence P Cescon, Department of Hematology Oncology, Reading Hospital, West Reading, PA 19611, USAFollow
Wei Jiang
Ronald Myers
Qiang Wei
Bingshan Li
Massimo Cristofanilli
Hushan Yang

Document Type

Article

Publication Date

6-10-2022

Abstract

Previously undescribed molecular mechanisms of resistance will emerge with the increased use of cyclin-dependent kinase 4/6 inhibitors in clinical settings. To identify genomic aberrations in circulating tumor DNA associated with treatment resistance in palbociclib-treated metastatic breast cancer (MBC) patients, we collected 35 pre- and post-treatment blood samples from 16 patients with estrogen receptor-positive (ER

Publication Title

Cancers (Basel)

Volume

14

Issue

12

First Page

2872

Recommended Citation

Abu-Khalaf, M., Wang, C., Zhang, Z., Luo, R., Chong, W., Silver, D., Fellin, F., Jaslow, R., Lopez, A., Cescon, T., Jiang, W., Myers, R., Wei, Q., Li, B., Cristofanilli, M., & Yang, H. (2022). Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism.. Cancers (Basel), 14 (12), 2872. https://doi.org/https://doi.org/10.3390%2Fcancers14122872